CN111386337A - 包含胸腺素β4或其衍生物作为活性成分的用于促进杯状细胞增殖或粘蛋白分泌的组合物 - Google Patents

包含胸腺素β4或其衍生物作为活性成分的用于促进杯状细胞增殖或粘蛋白分泌的组合物 Download PDF

Info

Publication number
CN111386337A
CN111386337A CN201880076169.1A CN201880076169A CN111386337A CN 111386337 A CN111386337 A CN 111386337A CN 201880076169 A CN201880076169 A CN 201880076169A CN 111386337 A CN111386337 A CN 111386337A
Authority
CN
China
Prior art keywords
thymosin
composition
mucin
goblet cell
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880076169.1A
Other languages
English (en)
Chinese (zh)
Inventor
姜信旭
金京洵
梁元硕
成智惠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HLB Therapeutics Co Ltd
Original Assignee
G TreeBNT Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G TreeBNT Co Ltd filed Critical G TreeBNT Co Ltd
Publication of CN111386337A publication Critical patent/CN111386337A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201880076169.1A 2017-11-24 2018-11-23 包含胸腺素β4或其衍生物作为活性成分的用于促进杯状细胞增殖或粘蛋白分泌的组合物 Pending CN111386337A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762590444P 2017-11-24 2017-11-24
US62/590,444 2017-11-24
PCT/KR2018/014522 WO2019103523A2 (ko) 2017-11-24 2018-11-23 티모신 베타 4 또는 이의 유도체를 유효성분으로 포함하는 술잔세포 증식 또는 뮤신 분비 촉진용 조성물

Publications (1)

Publication Number Publication Date
CN111386337A true CN111386337A (zh) 2020-07-07

Family

ID=66630753

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880076169.1A Pending CN111386337A (zh) 2017-11-24 2018-11-23 包含胸腺素β4或其衍生物作为活性成分的用于促进杯状细胞增殖或粘蛋白分泌的组合物

Country Status (8)

Country Link
US (1) US20200353052A1 (enExample)
EP (1) EP3715451A4 (enExample)
JP (1) JP2021504349A (enExample)
KR (1) KR20200081402A (enExample)
CN (1) CN111386337A (enExample)
AU (1) AU2018372396A1 (enExample)
CA (1) CA3083101A1 (enExample)
WO (1) WO2019103523A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111888463A (zh) * 2020-08-18 2020-11-06 华中农业大学 用于治疗抑郁症的胸腺素β4药物制剂与制备方法及其应用
CN112023027A (zh) * 2020-07-21 2020-12-04 广东海洋大学 胸腺素或其衍生物的应用和治疗快感缺乏型抑郁症的药物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024233903A1 (en) * 2023-05-11 2024-11-14 Wayne State University Combination treatments to promote epithelial integrity and treat ocular disorders
KR20250098014A (ko) * 2023-12-21 2025-07-01 주식회사 비제이와이 탈모 예방 또는 발모 촉진용 흉선 유래 펩타이드 유도체 및 이의 이용

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1638789A (zh) * 2001-03-15 2005-07-13 雷金纳克斯生物制药公司 用胸腺素β4(Tβ4)、类似物、异构体及其它衍生物治疗眼睛和周围组织失调的方法
US20060264360A1 (en) * 2002-04-12 2006-11-23 Yale University Office Of Cooperstive Research Anti-inflammatory and wound healing effects of lymphoid thymosin beta-4
CN1896096A (zh) * 2005-07-15 2007-01-17 北京诺思兰德生物技术有限责任公司 基因工程方法生产的高活性胸腺素β4衍生物
CN1935838A (zh) * 2005-09-23 2007-03-28 北京诺思兰德生物技术有限责任公司 胸腺素β4衍生物及其应用
US20130203684A1 (en) * 2010-09-30 2013-08-08 Regenerx Biopharmaceuticals, Inc. Method of achieving a thymosin beta 4 concentration in a human patient
CN106692949A (zh) * 2016-12-23 2017-05-24 北京诺思兰德生物技术股份有限公司 一种用于治疗眼部疾病的药物及其组合物
US20170333531A1 (en) * 2014-10-22 2017-11-23 G-Treebnt Co., Ltd. Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
US20180280479A1 (en) * 2017-03-03 2018-10-04 G-Treebnt Co., Ltd. Stabilized external preparation comprising thymosin beta 4 as an active ingredient

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032392A (en) * 1986-09-04 1991-07-16 Vision Pharmaceuticals Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
US20110020449A1 (en) * 1998-07-30 2011-01-27 Regenerx Biopharmaceuticals, Inc. Methods of treating disorders of the eye and surrounding tissue with thymosin beta 4 (tb4), analogues, isoforms and other derivatives
US20090131313A1 (en) * 2005-06-17 2009-05-21 Regenerx Biopharmaceuticals, Inc. Lkktet and/or lkktnt peptide compositions and methods for treating or preventing tissue deterioration, injury or damage
WO2009033814A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
KR20160047321A (ko) * 2014-10-22 2016-05-02 주식회사 지트리파마슈티컬 티모신 베타 4 를 함유하는 조성물

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1638789A (zh) * 2001-03-15 2005-07-13 雷金纳克斯生物制药公司 用胸腺素β4(Tβ4)、类似物、异构体及其它衍生物治疗眼睛和周围组织失调的方法
US20060264360A1 (en) * 2002-04-12 2006-11-23 Yale University Office Of Cooperstive Research Anti-inflammatory and wound healing effects of lymphoid thymosin beta-4
CN1896096A (zh) * 2005-07-15 2007-01-17 北京诺思兰德生物技术有限责任公司 基因工程方法生产的高活性胸腺素β4衍生物
CN1935838A (zh) * 2005-09-23 2007-03-28 北京诺思兰德生物技术有限责任公司 胸腺素β4衍生物及其应用
US20130203684A1 (en) * 2010-09-30 2013-08-08 Regenerx Biopharmaceuticals, Inc. Method of achieving a thymosin beta 4 concentration in a human patient
US20170333531A1 (en) * 2014-10-22 2017-11-23 G-Treebnt Co., Ltd. Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
CN106692949A (zh) * 2016-12-23 2017-05-24 北京诺思兰德生物技术股份有限公司 一种用于治疗眼部疾病的药物及其组合物
US20180280479A1 (en) * 2017-03-03 2018-10-04 G-Treebnt Co., Ltd. Stabilized external preparation comprising thymosin beta 4 as an active ingredient

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112023027A (zh) * 2020-07-21 2020-12-04 广东海洋大学 胸腺素或其衍生物的应用和治疗快感缺乏型抑郁症的药物
CN112023027B (zh) * 2020-07-21 2023-03-14 广东海洋大学 胸腺素或其衍生物的应用和治疗快感缺乏型抑郁症的药物
CN111888463A (zh) * 2020-08-18 2020-11-06 华中农业大学 用于治疗抑郁症的胸腺素β4药物制剂与制备方法及其应用

Also Published As

Publication number Publication date
AU2018372396A1 (en) 2020-06-25
CA3083101A1 (en) 2019-05-31
EP3715451A2 (en) 2020-09-30
KR20200081402A (ko) 2020-07-07
WO2019103523A2 (ko) 2019-05-31
WO2019103523A3 (ko) 2019-07-18
EP3715451A4 (en) 2021-07-21
US20200353052A1 (en) 2020-11-12
JP2021504349A (ja) 2021-02-15

Similar Documents

Publication Publication Date Title
US20120315256A1 (en) Use of transforming growth factor - beta 1 (tgf-b1) inhibitor peptides for the treatment of corneal fibrosis and/or haze
EP1933852B1 (en) Amniotic membrane preparations and purified compositions and methods of use
CN111386337A (zh) 包含胸腺素β4或其衍生物作为活性成分的用于促进杯状细胞增殖或粘蛋白分泌的组合物
JP3058920B2 (ja) アルブミンを有効成分とする医薬組成物
AU2008261127A1 (en) Methods for Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta 4 (TBeta4), Analogues, Isoforms and Other Derivatives
TW201822785A (zh) 包含pedf-衍生之短肽之組合物及其用途
US20240041977A1 (en) Annexin a1 n-terminal peptide formulations and methods
CN116421704A (zh) 多肽pd-dp-005在制备治疗肺部疾病药物中的应用及其药物
CN1315531C (zh) 用于眼睛干燥及与眼睛干燥相关的疾病的治疗剂
US6221846B1 (en) Ophthalmic drug compositions
AU2002255736A1 (en) Methods of Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta4 (TBeta4), Analogues, Isoforms and Other Derivatives
KR20080031195A (ko) 각결막 질환의 예방 또는 치료제
CN104394881B (zh) 修饰的人肿瘤坏死因子受体-1多肽的新用途
JP2020530435A (ja) Ｇｌｙ−Ｔβ４（Ｇｌｙ−チモシンβ４）を含有する眼球乾燥症の治療用薬学的組成物
HK40023769A (en) Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient
JPH05310592A (ja) 創傷治療剤及び医薬製剤
EP4574211A2 (en) Compositions of growth factor for the treatment of eye disease
WO2022183360A1 (en) Short synthetic peptide and their uses for treating dry eye disease
TW202506704A (zh) 具有改善乾眼症活性的新型胜肽及包括其之藥物組合物
KR20170021667A (ko) 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물
JPH03218321A (ja) 抗脳浮腫用医薬組成物
HK1241379B (zh) 短合成肽及其治疗和/或预防乾眼症的用途
HK1074577B (en) THE USE OF THYMOSIN β4 (Tβ4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING DISORDERS OF EYE AND THE SURROUNDING TISSUE

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40023769

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Gyeonggi Do, South Korea

Applicant after: HLB Medical Co.,Ltd.

Address before: Gyeonggi Do, South Korea

Applicant before: G-TREEBNT Co.,Ltd.

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200707